Equity Overview
Price & Market Data
Price: $3.96
Daily Change: $0.00 / 0.00%
Daily Range: $3.75 - $4.09
Market Cap: $236,013,536
Daily Volume: 730,729
Performance Metrics
1 Week: -4.12%
1 Month: -4.12%
3 Months: 0.76%
6 Months: -15.38%
1 Year: 16.13%
YTD: 0.76%
Company Details
Employees: 141
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.